Please ensure Javascript is enabled for purposes of website accessibility

Amylin Gets Some FDA Love

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA.

An approving nod from the Food and Drug Administration gave Amylin Pharmaceuticals (NASDAQ:AMLN) stock a big boost -- more than 17% yesterday, and an additional 7% so far today.

The FDA will accept Amylin's alternate plan to prove that the once-weekly version of diabetes drug Byetta, which is made at its new commercial-scale plant, is the same as the drug used in the clinical trials. Plan A, to use laboratory data, was rejected by the FDA last month.

Plan B involves using patients in the maintenance phase of the pivotal phase 3 trial, who have already been switched to the commercial-scale drug. Assuming the data from the maintenance phase looks like the data from earlier in the trial, Amylin, marketing partner Eli Lilly (NYSE:LLY), and development partner Alkermes (NASDAQ:ALKS) should be able to gain approval for the drug.

Plan C, the backup to the backup plan, was to run a new trial with the drug from the new plant. It's a good thing this won't be needed, as it likely would have pushed the filing for the marketing application beyond the first half of next year. Investors are clearly excited about avoiding this delay.

With an FDA decision on Novo Nordisk's (NYSE:NVO) liraglutide expected in the spring, and sales of Byetta running into tough competition from oral diabetes medications like Merck's (NYSE:MRK) Januvia and GlaxoSmithKline's (NYSE:GSK) Avandia, Amylin really needs the once-weekly version approved. Yesterday's announcement got it one giant step closer.

Novo Nordisk is a Motley Fool Global Gains selection. Eli Lilly and GlaxoSmithKline are Income Investor recommendations. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.04 (0.50%) $0.45
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$316.82 (2.10%) $6.51
GSK Stock Quote
$34.70 (-1.59%) $0.56
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$104.81 (-0.48%) $0.51
Alkermes plc Stock Quote
Alkermes plc
$25.61 (-3.18%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.